αA-crystallin Inhibitors
αA-crystallin inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of αA-crystallin, a small heat shock protein that plays a crucial role in maintaining the structural integrity and transparency of the lens in the eye. αA-crystallin, along with its closely related partner αB-crystallin, functions as a molecular chaperone, preventing the aggregation of misfolded or damaged proteins under conditions of cellular stress. This chaperone activity is vital for preserving the clarity of the lens, as protein aggregation can lead to clouding and loss of transparency. αA-crystallin is also involved in protecting cells from various types of stress, including oxidative damage and thermal stress, by stabilizing the cytoskeleton and preventing apoptosis. By inhibiting αA-crystallin, researchers can disrupt these protective functions, providing a tool to study the specific role of this protein in cellular homeostasis and lens biology.
In research, αA-crystallin inhibitors are valuable for exploring the mechanisms by which αA-crystallin contributes to protein homeostasis and cellular stress responses, particularly in the lens of the eye. By blocking the activity of αA-crystallin, scientists can investigate the consequences of impaired chaperone function, such as increased protein aggregation and the resulting cellular and tissue-level effects. This inhibition can lead to a deeper understanding of the processes that underlie protein aggregation disorders and the role of crystallins in maintaining lens transparency over a lifetime. Additionally, αA-crystallin inhibitors allow researchers to study the broader implications of small heat shock protein function in other tissues, where αA-crystallin and similar proteins play roles in cytoskeletal organization and cellular protection. Through these studies, the use of αA-crystallin inhibitors contributes to our knowledge of protein aggregation, chaperone-mediated protection, and the critical functions of crystallins in maintaining cellular and tissue integrity under stress conditions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin, a polyphenolic compound found in turmeric, inhibits αA-crystallin indirectly by modulating the NF-κB signaling pathway. It interferes with the activation of NF-κB, a key transcription factor involved in inflammation. Curcumin inhibits IκB kinase, preventing the degradation of IκB and subsequent NF-κB activation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate (EGCG), a major polyphenol in green tea, indirectly inhibits αA-crystallin by influencing the PI3K/Akt pathway. EGCG targets the PI3K/Akt pathway by suppressing Akt phosphorylation, which plays a role in the regulation of αA-crystallin expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a pyridinyl imidazole compound, is a p38 MAP kinase inhibitor that indirectly affects αA-crystallin. By inhibiting p38 MAP kinase, SB203580 disrupts the MAPK signaling pathway, leading to altered transcriptional regulation of αA-crystallin. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a fungal metabolite, acts as a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly inhibiting αA-crystallin. PI3K is involved in the Akt signaling pathway, and wortmannin disrupts this pathway by blocking PI3K activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a selective JNK inhibitor, indirectly modulates αA-crystallin expression by targeting the JNK signaling pathway. By inhibiting JNK, SP600125 disrupts the phosphorylation of c-Jun, a downstream target of JNK. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a synthetic inhibitor of PI3K, indirectly inhibits αA-crystallin by disrupting the PI3K/Akt signaling pathway. LY294002 blocks PI3K activity, preventing the phosphorylation and activation of Akt. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a specific MEK inhibitor, indirectly inhibits αA-crystallin by targeting the MAPK/ERK signaling pathway. It blocks the activation of MEK, a kinase upstream of ERK. | ||||||
LY2228820 | 862507-23-1 | sc-364525 | 5 mg | $191.00 | 1 | |
LY2228820, a specific p38 MAP kinase inhibitor, indirectly affects αA-crystallin by modulating the MAPK signaling pathway. By inhibiting p38 MAP kinase, LY2228820 disrupts the signaling cascade that leads to the transcriptional regulation of αA-crystallin. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly inhibits αA-crystallin by disrupting the mTOR signaling pathway. It forms a complex with FKBP12, inhibiting mTORC1 activity. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
LY303511, a specific PI3K inhibitor, indirectly inhibits αA-crystallin by disrupting the PI3K/Akt signaling pathway. LY303511 blocks PI3K activity, preventing the phosphorylation and activation of Akt. | ||||||